Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan technique could reveal hidden COVID-19 lung signs

NCT ID NCT04512118

Diagnosis Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether PET-CT scans can detect unique signs of COVID-19 in the lungs. Researchers scanned 22 patients suspected of having lung infections and compared the images to their COVID-19 test results. The goal was to find patterns that could help diagnose COVID-19 more accurately using this imaging method.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-FDG (a radioactive tracer used in PET-CT scans)
What this could lead to
If successful, this could help doctors better identify COVID-19 lung infections using PET-CT scans, leading to faster and more accurate diagnosis.
What could go wrong
This was a small, completed study with only 22 patients, so results may not apply to everyone. It focused on imaging patterns, not treatment, so it won't directly change patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

22 people

The number who actually took part.

Started

Mar 2020

Finished

Jul 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with suspicion of lung involvement in COVID19 context

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient coming to nuclear medicine for 18F-flurodesoxyglucose (FDG) positron emission tomography computed tomography (PET-CT) with suspicion of lung involvement * patient affiliated to a social security scheme or equivalent * adult patient having been informed of the study Exclusion Criteria: * patient with a negative covid 19 test

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Presence of COVID-19 compatible CT abnormalities are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Presence of COVID-19 compatible CT abnormalities

Contacts and locations

Locations

  • CHRU of Nancy

    Vandœuvre-lès-Nancy, Grand Est, 54511, France